IP Verse

Accord BioPharma, Inc. et al. - IPR2026-00259

Explore the PTAB proceeding IPR2026-00259 filed by Accord BioPharma, Inc. et al. on Mar 20, 2026. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2026-00259
Filing Date
Mar 20, 2026
Petitioner
Accord BioPharma, Inc. et al.
Status
Pending
Respondent Application Number
17237650
Respondent Tech Center
1600
Respondent Patent Number
12291566

Decision Documents New

Decision pending - set alert to receive updates

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Notice filing date accorded

Mar 27, 2026PAPERBOARD

EX1001 - U.S. Patent No. 11,041,020 to Harrison et al. (June 22, 2021)

Mar 20, 2026EXHIBITPETITIONER

EX1002 - U.S. Patent No. 11,014,982 to Harrison et al. (May 25, 2021)

Mar 20, 2026EXHIBITPETITIONER

EX1003 - U.S. Patent No. 12,122,824 to Harrison et al. (Oct. 22, 2024)

Mar 20, 2026EXHIBITPETITIONER

EX1004 - U.S. Patent No. 12,291,566 to Harrison et al. (May 6, 2025)

Mar 20, 2026EXHIBITPETITIONER

EX1007 - Excerpts from prosecution history of U.S. Appl'n No. 16/517,594

Mar 20, 2026EXHIBITPETITIONER

EX1008 - Excerpts from prosecution history of U.S. Appl'n No. 16/517,592

Mar 20, 2026EXHIBITPETITIONER

EX1009 - Excerpts from prosecution history of U.S. Appl'n No. 17/320,490

Mar 20, 2026EXHIBITPETITIONER

EX1010 - Excerpts from prosecution history of U.S. Appl'n No. 17/237,650

Mar 20, 2026EXHIBITPETITIONER

EX1011 - ClinicalTrials.gov, NCT02181673 (Version 23)

Mar 20, 2026EXHIBITPETITIONER

EX1012 - M. E. Weinblatt, et al., Intravenous golimumab is effective

Mar 20, 2026EXHIBITPETITIONER

EX1013 - M. Rossini, et al., Why golimumab in the treatment

Mar 20, 2026EXHIBITPETITIONER

EX1014 - ClinicalTrials.gov, NCT02186873 (Version 24)

Mar 20, 2026EXHIBITPETITIONER

EX1015 - U.S. National Library of Medicine, ClinicalTrials.gov, NCT02186873

Mar 20, 2026EXHIBITPETITIONER

EX1016 - R. D. Inman, et al., Efficacy and Safety of Golimumab

Mar 20, 2026EXHIBITPETITIONER

EX1017 - Six Sigma

Mar 20, 2026EXHIBITPETITIONER

EX1018 - BLA Approved re BLA 125289, FOOD AND DRUG ADMIN. (Apr. 24, 2009)

Mar 20, 2026EXHIBITPETITIONER

EX1019 - BLA Approved re BLA 125433, FOOD AND DRUG ADMIN. (July 18, 2013)

Mar 20, 2026EXHIBITPETITIONER

EX1022 - S. D’Angelo, Psoriatic arthritis: treatment strategies

Mar 20, 2026EXHIBITPETITIONER

EX1024 - U.S. Patent Publication 2009/0123378 to Wong et al.

Mar 20, 2026EXHIBITPETITIONER

EX1025 - International Publication WO 2008/063213 A2 to Medich et al.

Mar 20, 2026EXHIBITPETITIONER

EX1026 - J. Kay & M. U. Rahman, Golimumab (Kay, 2009)

Mar 20, 2026EXHIBITPETITIONER

EX1027 - E. C. Keystone & C. F. Ware, Tumor Necrosis

Mar 20, 2026EXHIBITPETITIONER

EX1028 - H. Shim, One target, different effects (Shim, 2011)

Mar 20, 2026EXHIBITPETITIONER

EX1029 - J. Kalden, Anti-TNF therapy: what have we learned in 12 years?

Mar 20, 2026EXHIBITPETITIONER

EX1030 - L. C. Coates, et al., Anti-TNF therapy in ankylosing spondylitis

Mar 20, 2026EXHIBITPETITIONER

EX1032 - SIMPONI ARIA (golimumab) injection, for intravenous use

Mar 20, 2026EXHIBITPETITIONER

EX1033 - D. van der Heijde, et al., The Effect of Golimumab Therapy

Mar 20, 2026EXHIBITPETITIONER

EX1034 - Administrative and Correspondence Documents, 125433Orig1s000

Mar 20, 2026EXHIBITPETITIONER

EX1035 - M. K. Doyle et al., Effects of subcutaneous and intravenous

Mar 20, 2026EXHIBITPETITIONER

EX1036 - U.S. Publication No. 2008/0311043 to Hoffman et al. (“Hoffman”)

Mar 20, 2026EXHIBITPETITIONER

EX1037 - U.S. Patent No. 5,656,272 to Le et al. (“Le”)

Mar 20, 2026EXHIBITPETITIONER

EX1038 - Y. Zhuang, et al., Golimumab Pharmacokinetics

Mar 20, 2026EXHIBITPETITIONER

EX1039 - New Phase 3 Data Show Simponi Aria® (Golimumab)

Mar 20, 2026EXHIBITPETITIONER

EX1040 - New Phase 3 Data Show SIMPONI ARIA ® (golimumab)

Mar 20, 2026EXHIBITPETITIONER

EX1041 - A. Kavanaugh, et al., Golimumab, a New Human Tumor Necrosis(2009)

Mar 20, 2026EXHIBITPETITIONER

EX1042 - A. Kavanaugh, et al., Golimumab in Psoriatic Arthritis (2012)

Mar 20, 2026EXHIBITPETITIONER

EX1043 - A. Kavanaugh, et al., Patient-Reported Outcomes (2013)

Mar 20, 2026EXHIBITPETITIONER

EX1044 - A. Kavanaugh, et al., Clinical efficacy, radiographic (2014)

Mar 20, 2026EXHIBITPETITIONER

EX1050 - Appendix 6 Summary, CADTH (July 2015)

Mar 20, 2026EXHIBITPETITIONER

EX1051 - Industry Guidance (May 1998)

Mar 20, 2026EXHIBITPETITIONER

EX1006 - Dr. Roy M. Fleischmann curriculum vitae

Mar 20, 2026EXHIBITPETITIONER

EX1052 - National Library of Medicine (2000)

Mar 20, 2026EXHIBITPETITIONER

EX1005 - Declaration of Dr. Roy M. Fleischmann in Support of IPR Petition

Mar 20, 2026EXHIBITPETITIONER

Inter Partes Review Petition of U.S. Patent 12,291,566

Mar 20, 2026PAPERPETITIONER

Power of Attorney of Accord BioPharma, Inc.

Mar 20, 2026PAPERPETITIONER

Power of Attorney of Bio-Thera Solutions, Ltd.

Mar 20, 2026PAPERPETITIONER

Power of Attorney of Intas Pharmaceuticals, Ltd.

Mar 20, 2026PAPERPETITIONER

Notice of Sotera Stipulation

Mar 20, 2026PAPERPETITIONER